David J. Mack - 31 Oct 2025 Form 4 Insider Report for BioXcel Therapeutics, Inc. (BTAI)

Reporting relationship: Director
Issuer ticker: BTAI
Reported as of: 31 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 03 Nov 2025, 20:00:23 UTC
Prior SEC filing: 01 Oct 2025
Next SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Richard Steinhart, Attorney-in-Fact for David J. Mack

Key filing fact

David J. Mack filed Form 4 for BioXcel Therapeutics, Inc. (BTAI) on 03 Nov 2025.

Key facts

This page summarizes David J. Mack's Form 4 filing for BioXcel Therapeutics, Inc. (BTAI).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 03 Nov 2025, 20:00.

Change

Previous filing in this sequence was filed on 01 Oct 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001694466 Primary reporting owner

MACK DAVID J.

Relationship: Director
Address: C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, 12TH FLOOR, NEW HAVEN
Signature: /s/ Richard Steinhart, Attorney-in-Fact for David J. Mack
Signature date: 03 Nov 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BTAI transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,694
Change %: +9.1%
Price
Shares after: 20,317
Date: 31 Oct 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BTAI transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -1,694
Change %: -100%
Price: $0.000000
Shares after: 0
Date: 31 Oct 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,694
Exercise price
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.

Footnote F2

On November 21, 2024, the Reporting Person was granted 20,317 RSUs, vesting in twelve equal installments on the last date of each month beginning on November 30, 2024, subject to his continued service as a Director through the vesting period.